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Abstract The impact of imatinib dose on response rates and
survival in older patients with chronic myeloid leukemia in
chronic phase has not been studied well. We analyzed data
from the German CML-Study IV, a randomized five-arm
treatment optimization study in newly diagnosed BCR-
ABL-positive chronic myeloid leukemia in chronic phase.
Patients randomized to imatinib 400 mg/day (IM400) or ima-
tinib 800 mg/day (IM800) and stratified according to age
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(≥65 years vs. <65 years) were compared regarding dose,
response, adverse events, rates of progression, and survival.
The full 800 mg dose was given after a 6-week run-in period
with imatinib 400 mg/day. The dose could then be reduced
according to tolerability. A total of 828 patients were random-
ized to IM400 or IM800. Seven hundred eighty-four patients
were evaluable (IM400, 382; IM800, 402). One hundred ten
patients (29 %) on IM400 and 83 (21 %) on IM800 were
≥65 years. The median dose per day was lower for patients
≥65 years on IM800, with the highest median dose in the first
year (466 mg/day for patients ≥65 years vs. 630 mg/day for
patients <65 years). Older patients on IM800 achieved major
molecular remission and deep molecular remission as fast as
younger patients, in contrast to standard dose imatinib with
which older patients achieved remissions much later than
younger patients. Grades 3 and 4 adverse events were similar
in both age groups. Five-year relative survival for older pa-
tients was comparable to that of younger patients. We suggest
that the optimal dose for older patients is higher than 400 mg/
day. ClinicalTrials.gov identifier: NCT00055874
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imatinib dosages
Introduction
Older patients with chronic myeloid leukemia (CML) are
underrepresented in clinical trials as the median age of patients
included in clinical trials is lower compared to the general
population (54 years [1] vs. >60 years [2–4]). The IRIS trial
[5], which led to approval of imatinib for chronic-phase (CP)
CML, excluded patients over 70 years of age.
The impact of age on therapy and outcome has already
been discussed in the interferon alpha (IFN) era [6]. In the
imatinib era, the outcome of older patients with CML has
been studied in several trials [7–13]. Most trials stratified
patients by age in a group of older and a group of
younger patients. Some trials included patients on different
imatinib doses, but did not analyze dose effects on treat-
ment response [8–10]. Rosti et al. reported on 284 patients
in late CP CML treated with imatinib 400 mg/day. Com-
plete cytogenetic remission (CCR) rates were lower in
older patients (≥65 years) than in younger patients
(<65 years) with more adverse events (AEs) in older
patients, but nevertheless, overall survival (OS) was the
same in both age groups [7]. Latagliata et al. analyzed
117 patients in early CP CML under imatinib treatment
with 300, 400, or 800 mg/day. No significant difference in
the rate of CCR was reported in older (≥65 years) com-
pared to younger (<65 years) patients. AEs (WHO grades
3–4) were more frequent, and rates of dose reduction to
≤300 mg/day and discontinuation of imatinib were higher
in older patients [8]. Cortes et al. reported on 187 patients
in early CP that were treated with imatinib 400 or 600–
800 mg/day. Twenty-six percent of patients were 60 years
or older. With a median follow-up of 16 months, similar
rates of CCR were observed in both age groups [9]. More
recently, Gugliotta et al. reported similar rates of CCR and
major molecular remission (MMR) in 115 patients
≥65 years among 559 patients in early CP treated with
imatinib 400 or 800 mg/day [10]. In a multicenter study
of high-dose imatinib in 115 newly diagnosed patients in
CP, Cortes et al. reported a similar dose intensity and no
difference in AEs at any severity for patients <65 and
≥65 years. MMR was achieved by 79 % of patients who
received at least 90 % dose intensity (RIGHT study) [11].
Two trials addressing specifically older patients for long-
term safety and tolerability of imatinib did not investigate
dosage effects of imatinib [12, 13].
In contrast to the aforementioned studies, within the ran-
domized CML-Study IV [14], we analyzed the impact of
different imatinib dose regimens on response rates in
imatinib-treated older CML patients in comparison to younger
patients and suggest that the optimal dose for older patients is
higher than 400 mg/day.
Methods
Study design, patients, and goals The CML-Study IV is a
five-arm randomized trial comparing imatinib 400 mg/day
(IM400) vs. imatinib 800 mg/day (IM800) vs. imatinib
400 mg/day in combination with IFN vs. imatinib 400 mg/
day in combination with low-dose cytarabine vs. imatinib
after IFN failure in newly diagnosed BCR-ABL-positive CP
CML. During a pilot phase of 3 years, only high-risk patients
were assigned to imatinib 800 mg/day. In 2005, imatinib
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800mg/day was started as a full study arm [14, 15]. There was
no age limit.
Primary and secondary objectives were as described previ-
ously [14, 15]. Published analyses comprised impact of re-
mission rates on survival [14, 15], identification of prognostic
factors [16, 17], and outcome of patients transplanted after
imatinib pretreatment [18].
To evaluate the efficacy of imatinib in the elderly, patients
randomized to IM400 and IM800 were stratified according to
median age at diagnosis in western populations [3] (≥65 vs.
<65 years). For all four groups, effectively administered ima-
tinib dose, time to cytogenetic and molecular remissions, AEs
by World Health Organization (WHO) grading, probabilities
of progression to accelerated phase (AP) and blast crisis (BC)
and OS, and causes of death were analyzed.
Treatment Treatment and dose adaptation were as described
previously (see also legend to Table 2) [14, 15].
Definitions and endpoints Definitions for AP, BC, CCR,
MMR, and molecular remission ≤0.01 % on the international
scale (MR4) followed the recommendations of the European
LeukemiaNet and the standardized definitions of molecular
response [19, 20]. OS was defined as the time between diag-
nosis and death of any cause whether on or off tyrosine kinase
inhibitor (TKI). All living patients were censored at the time
of their last visit. In estimating the cumulative incidences (CI)
of molecular or cytogenetic remissions, patients were cen-
sored at the time they received a second-generation TKI or
were transplanted. Risk assignment was made by EURO [21]
and EUTOS scores [22].
Fig. 1 Flow diagram of
randomized and evaluable
patients. n number of patients,
IM400 imatinib 400 mg/day,
IM800 imatinib 800 mg/day,
CML chronic myeloid leukemia,
CP chronic phase, IC informed
consent, OS overall survival, IM
imatinib, y years, CCR complete
cytogenetic remission, MMR
major molecular remission, MR4
molecular remission ≤0.01 % on
the international scale
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Statistical analysis Baseline characteristics were compared
using the Mann–Whitney U test if continuous and the chi2
test if categorical. CI of CCR and MMR were calculated
considering competing risks [23, 24] defined by AP, BC,
and death. CI for AP and BC were calculated with “death
without prior progression” as competing event. Comparisons
were done by the Gray test [25].
OS curves were calculated by the Kaplan–Meier meth-
od and compared by the log-rank test. Relative overall
survival was calculated by dividing the observed survival
probabilities by the expected survival probability of the
general German population matching age and sex. Analy-
ses were according to intention-to-treat; only AEs were
analyzed as treated. Level of significance was 0.05. Since
this analysis was not prespecified and p values were not
adjusted, the results have to be interpreted as exploratory.
Calculations were performed with the SAS software ver-
sion 9.1.3 and R 2.15.0.
Cytogenetic and molecular analyses Cytogenetic and molec-
ular analyses were performed as described previously [14, 20,
26, 27].
Ethics The protocol followed the Declaration of Helsinki
and was approved by the ethics committee of the
Medizinische Fakultät Mannheim and by local ethics
committees of participating centers. Written informed
consent was obtained from all patients before they en-
tered the study.
Results
Patients From July 2002 to March 2012, 1,551 patients were
randomized, 828 of these to IM400 or IM800 (Fig. 1). A total
of 784 patients were evaluable for follow-up, 382 in the
IM400 and 402 in the IM800 arm. One hundred ninety-three
patients were ≥65 years, 591 <65 years. Of the older patients,
110 patients were randomized to IM400 and 83 patients to
IM800. The median observation time on IM800 was
50.9 months in the elderly and 50.1 months in the younger
group, and on IM400, 63.0 months in the elderly and
67.6 months in the younger group. Data entry was closed on
May 24, 2012.
The median age of patients was 52 years (IM400,
53 years; IM800, 51 years). Differences between the
two age groups were noted in Karnofsky performance
index, hemoglobin, spleen size, and white blood cell
counts (Table 1).
The median dose per day for the entire observation time
was lower for older patients on IM800 (421 mg/day for
patients ≥65 years vs. 556 mg/day for patients <65 years) with
the highest median dose in the first year (466 mg/day for
patients ≥65 years vs. 630 mg/day for patients <65 years),
but not different for both age groups on IM400 (400 mg/day
each). The dynamics of dose adaptation were analyzed in 3-
month periods during the first 24 months of treatment for all
four patients groups (Table 2). Cutoff values of 390 and
790 mg/day have been chosen to distinguish between the
patients that really changed dose and those that only
Table 1 Characteristics of patients at baseline
IM400 IM800 p value,
IM400/IM800 combined
Age (years), (n) <65 (272) ≥65 (110) <65 (319) ≥65 (83) <65 vs. ≥65
Age (years), median (range) 48 (16–64) 70 (65–88) 46 (18–64) 69 (65–85) –
Sex female (%) 38 45 41 41 ns
Karnofsky index (%) 0–85 11 16 10 18 0.03
90–95 31 38 31 30 0.03
100 58 46 59 52 0.03
Hemoglobin (g/dl), median (range) 12.1 (4.9–17.5) 12.8 (6.4–16.2) 12.1 (4.7–19.1) 12.4 (6.5–15.7) <0.01
White blood cell count ×109/l, median (range) 81.6 (5.7–574) 58.0 (6.6–582) 93.8 (2.6–554) 43.8 (5.1–570) <0.01
Platelets ×109/l, median (range) 373 (89–2,419) 390 (58–2,337) 388 (39–2,582) 400 (88–2,716) ns
Spleen size (cm below costal margin), median
(range)
2 (0–28) 0 (0–16) 2 (0–30) 0 (0–23) <0.01
EURO score (%) Low 45 11 45 12 nda
Intermediate 42 77 42 72 nda
High 13 12 13 16 nda
EUTOS score (%) Low 87 91 85 86 ns
High 13 9 15 14 ns
n number of patients, IM400 imatinib 400 mg/day, IM800 imatinib 800 mg/day, ns not significant, nd not done
a Since the EURO score depends on age by definition, no test was conducted
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discontinued imatinib for one or two days, e.g., due to AEs.
The 47.5 % of younger patients and 18.4 % of older patients
on IM800 received an imatinib dosage between 790 and
800 mg/day in the second 3-month period with the highest
dose in older patients at 494 mg/day in the second 3-month
period. Thereafter, the dose decreased to 400 mg/day by
months 6–9. In younger patients, the highest median dosage
on IM800 was 773 mg/day in the second 3-month period,
which decreased to 600 mg/day by months 9–12.
Comparison of responses If treated with IM800, older pa-
tients achieved MMR and MR4 as fast as younger patients
(Fig. 2a, b).Median times toMMRwere 11.9 vs. 10.5months,
respectively. Median times toMR4 were 24.2 vs. 26.1 months,
respectively. In contrast, if treated with IM400, older patients
achieved MMR and MR4 significantly later than younger
patients (MMR p=0.013; Fig. 2a; MR4 p=0.012; Fig. 2b).
Median times to MMR were 18.1 vs. 15.9 months, and to
MR4 54.4 vs. 33.3 months, respectively. Regarding CCR,
median times to CCR on IM800 were 9.0 vs. 9.7 months, and
on IM400 14.8 vs. 12.0 months, respectively. The difference
between age groups on IM400 did not reach significance
(Fig. 2c).
AEs One hundred sixty-nine patients ≥65 years and 542 pa-
tients <65 years were evaluated for AEs during the initial
24 months. There was no significant difference between age
groups for higher-grade (WHO grades 3 and 4) hematologic
Table 2 Dose adaptation of imatinib during the first 24 months
IM400 IM800
Age (years) <65 ≥65 <65 ≥65
Months Doses
Median (mg/day)
0–3 400 400 563 472
3–6 400 400 773 494
6–9 400 400 629 400
9–12 400 400 600 400
12–15 400 400 600 400
15–18 400 400 600 400
18–21 400 400 600 400
21–24 400 400 600 400
<390 mg/day (%)
0–3 3.5 4.9 1.3 0.0
3–6 6.4 4.0 4.3 2.6
6–9 5.8 3.2 3.6 0.0
9–12 4.9 3.4 2.2 0.0
12–15 3.4 4.7 2.0 1.5
15–18 3.2 3.7 1.3 1.6
18–21 2.8 3.8 2.2 0.0
21–24 2.5 4.0 2.4 0.0
390–410 mg/day (%)
0–3 94.6 94.1 21.8 39.0
3–6 91.0 95.0 20.8 36.8
6–9 89.2 95.7 32.2 58.0
9–12 87.7 94.3 41.1 62.1
12–15 89.0 92.9 41.7 69.1
15–18 87.8 87.7 43.0 68.9
18–21 88.2 88.8 41.6 70.7
21–24 86.4 86.7 44.5 71.7
>410–599 mg/day (%)
0–3 1.5 0.9 41.6 36.6
3–6 1.1 0.0 11.6 23.7
6–9 3.1 1.1 9.2 8.7
9–12 4.5 2.3 4.5 12.1
12–15 3.8 0.0 4.0 3.4
15–18 2.7 6.2 3.4 3.3
18–21 2.4 3.8 3.1 3.5
21–24 4.0 2.7 1.0 3.8
600–790 mg/day (%)
0–3 0.4 0.0 14.5 8.5
3–6 0.8 0.0 12.9 18.4
6–9 1.5 0.0 7.1 15.9
9–12 2.1 0.0 3.4 10.6
12–15 0.0 2.4 4.4 8.8
15–18 4.1 0.0 9.8 6.6
18–21 4.2 0.0 9.7 8.6
21–24 4.0 0.0 8.1 9.4
Table 2 (continued)
IM400 IM800
Age (years) <65 ≥65 <65 ≥65
Months Doses
>790–800 mg/day (%)
0–3 0.0 0.0 18.8 15.9
3–6 0.8 1.0 47.5 18.4
6–9 0.4 0.0 44.3 17.4
9–12 0.8 0.0 44.8 15.2
12–15 0.0 0.0 41.7 16.2
15–18 2.3 1.2 42.6 19.7
18–21 2.4 3.8 42.9 17.2
21–24 3.0 4.0 43.5 0.0
Initial treatment for IM400 was imatinib 400 mg/day once daily. In case
of suboptimal response, a dose increase to 600 or 800 mg/day was
permitted. For IM800, the full 800 mg dose was given after a 6-week
run-in period with imatinib 400 mg/day to avoid excessive cytopenias.
The dose could then be reduced according to tolerability for maximum
patients’ adherence and to avoid clinical risks
IM400 imatinib 400 mg/day, IM800 imatinib 800 mg/day, % percent of
patients who were still on imatinib at the respective time points and
received these doses
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AEs. Leukocytopenia (all grades) in patients treated on IM800
and neurological AEs (all grades) in patients treated on IM400
were significantly less frequent in older patients (p=0.009 and
p=0.03, respectively). Some higher-grade non-hematologic
AEs were significantly more frequent in older than in younger
patients (IM400: dermatologic AEs, p=0.01; IM800: infec-
tions, p=0.03) (Table 3).
Progression and survival There was no difference between
age groups in probabilities of progression to AP or BC in an
analysis according to treatment groups (Fig. 3). Five-year OS
for patients ≥65 years was 78.2 % (IM400) and 87.5 %
(IM800), and for patients <65 years 92.8 % (IM400) and
92.5 % (IM800). Taking into account the German population
adjusted for age and sex [28], 5-year relative survival was
90.7 % for IM400 and 100.8 % for IM800, respectively, for
the older patients and 94.9 % and 94.4 %, respectively, for the
younger patients. In the elderly, death due to second malig-
nancies was more frequent than death due to progression
(Table 4).
Discussion
This is the first report that analyzes the effect of different
imatinib dose regimens in older vs. younger patients with
CML. The most important finding of our analysis is that older
patients on IM800 had no delay in reaching MMR and MR4,
as this was the fact with standard-dose imatinib where MMR
and MR4 were achieved significantly later than in younger
patients. We conclude that the superiority of the response rates
to IM800 was more pronounced in the older than in the
younger group. This effect is remarkable as the median dose
for older patients on IM800 was lower than that of younger
patients and only moderately higher than in older patients on
IM400. The result is in line with previous reports of this study
that superior cytogenetic and molecular remission rates were
reached in patients with IM800 [14].We think that this finding
is important, since superior molecular remission rates have
been shown to correlate with better survival [14, 15].
To avoid higher-grade AEs on IM800, imatinib was
adapted to tolerability in both age groups. Dose reductions
Age, years n Median, months p
IM800 ≥ 65 76 11.9
ns
IM800 < 65 302 10.5
IM400 ≥ 65 100 18.1
0.013
IM400 < 65 251 15.9
Years after diagnosis
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Age, years n Median, months p
IM800 ≥ 65 71 24.2
ns
IM800 < 65 284 26.1
IM400 ≥ 65 91 54.4
0.012
IM400 < 65 241 33.3
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Age, years n Median, months p
IM800 ≥ 65 80 9.0
ns
IM800 < 65 300 9.7
IM400 ≥ 65 100 14.8
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IM400 < 65 259 12.0
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Fig. 2 Molecular and cytogenetic remissions according to treatment groups. a Cumulative incidences of MMR, b cumulative incidences of MR4, and c
cumulative incidences of CCR. MMR major molecular remission, MR4 molecular remission ≤0.01 % on the international scale, CCR complete
cytogenetic remission, n number of patients, IM400 imatinib 400 mg/day, IM800 imatinib 800 mg/day, ns not significant
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were higher in older patients, although AEs grades 1–4 oc-
curred not more frequently than in younger patients. We
hypothesize that dose reductions in older patients were done
low-threshold compared to younger patients, to avoid clinical
risks in a frailer population. The observed differences in AEs
might be random. A similar dose intensity and no difference in
AEs was reported in high-dose imatinib therapy for patients
<65 and ≥65 years by Cortes et al. [11], whereas grades 3–4
hematologic and non-hematologic AEs were reported to be
more frequent in older patients with early CP CML by
Latagliata et al. [8] and in late CP treated with imatinib
400 mg/day by Rosti et al. [7].
It should be mentioned that most non-hematologic AEs
occurred more often in the IM800 arm, independent of age,
but since grades 3 and 4 AEs were similar between IM400 and
IM800, this appears tolerable with regard to a potentially
better outcome.
Given the observation that the effect of higher imatinib
dosages applied early in the course of treatment is more
pronounced in older than in younger patients, this could
explain the difference between results of this study and anoth-
er randomized trial of imatinib 400 vs. 800 mg/day [29], since
in the other study, the median age of the study population was
lower (47 vs. 52 years in our study) and patients older than
75 years were excluded, resulting in a lower number of
patients ≥65 years (15.5 % (personal written communication,
C. Piccolo, Novartis, November 18, 2013) vs. 24.6 % in our
study).
Since the median dosage for patients on the IM400 arm
was 400 mg/day for both age groups and the proportion of
patients who received doses <390 mg/day was similar, the
significantly later achievement of MMR and MR4 in older
patients on IM400 cannot be explained by non-adherence to
the prescribed medication and a lower than 400 mg dosage.
Table 3 Adverse events during
the initial 24 months
n number of patients, IM400
imatinib 400 mg/day, IM800
imatinib 800 mg/day, WHO
World Health Organization, %
percent of patients who had the
described adverse events, AEs
adverse events
a Number of patients for whom an
analysis was available. A total of
73 out of 784 patients were not
evaluable due to short observation
time (<24 months) and being
alive
b In addition, 276 patients were
not evaluable due to anemia
grades 1–4 at baseline
c In addition, 5 patients were not
evaluable due to leukocytopenia
grades 1–4 at baseline
d In addition, 35 patients were not
evaluable due to thrombocytope-
nia grades 1–4 at baseline
e In addition, 8 patients were not
evaluable due to missing informa-
tion about non-hematologic ad-
verse events
f In addition, 32 patients were not
evaluable due to anemia grades
3–4 at baseline
IM400 IM800
Age (years), (n) <65 (254a) ≥65 (96a) <65 (288a) ≥65 (73a)
Adverse events
WHO grades 1–4 (%)
Anemiab 51.4 61.4 53.1 54.9
Leukocytopeniac 56.7 58.3 64.7 48.0
Thrombocytopeniad 36.9 34.5 35.6 32.9
Myalgia/arthralgiae 19.0 11.7 28.9 20.8
Dermatologic AEse 12.6 14.9 27.5 33.3
Edemae 24.9 24.5 40.1 45.8
Gastrointestinal AEse 26.1 23.4 48.2 47.2
Neurological AEse 15.4 6.4 16.9 20.8
Infectione 6.3 4.3 12.0 15.3
Fatiguee 14.2 8.5 19.7 15.3
Allergy/immunologye 1.2 4.3 2.5 0
Constitutional symptomse 5.9 3.2 14.8 12.5
Othere 31.2 30.9 42.7 45.2
WHO grades 3 and 4 (%)
Anemiaf 3.8 6.4 5.1 7.0
Leukocytopenia 1.6 3.1 5.2 5.5
Thrombocytopenia 3.9 4.2 7.7 8.2
Myalgia/arthralgiae 2.8 1.1 2.5 1.4
Dermatologic AEse 0.4 5.4 2.8 2.8
Edemae 1.2 0 1.4 5.6
Gastrointestinal AEse 2.0 1.1 3.2 4.8
Neurological AEse 2.0 0 2.5 4.2
Infectione 0.8 0 2.5 8.3
Fatiguee 0.4 0 2.5 1.4
Allergy/immunologye 0 1.1 0.4 0
Constitutional symptomse 0.4 0 0.7 0
Othere 6.3 9.6 11.6 12.5
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The baseline characteristics beyond age seem to have no
influence, but the proportion of patients with lower Karnofsky
index was significantly higher in older patients.
To compare survival between age groups, the German
population adjusted for age and sex [28] was taken into
account. OS was reduced in older compared to younger pa-
tients due to a generally reduced life expectancy of older
people, whereas the 5-year relative survival of older patients
was comparable with that of younger patients. Nevertheless, it
is important to note that a bias in favor of the study patients is
likely. The relative survival estimates may be too optimistic,
since the exclusion criteria of CML-Study IV prevented the
participation of some of the frailest patients, e.g., those with
other neoplasias in need of treatment or with conditions
preventing study compliance and thus with a supposedly
reduced life expectancy. This would explain the better surviv-
al in older patients on IM800 (100.8 % at 5 years) than in the
general population.
In the pre-imatinib era, older age has been a poor prognos-
tic factor in CML [21, 30]. In the EUTOS score, which was
based on patients treated with imatinib, age is not included any
more. Since the EUTOS score refers to the endpoint CCR at
18 months [22], it has to be seen in the future whether age is
still an important risk factor for survival in patients with CML
under imatinib.
In conclusion, in older patients, higher molecular response
rates similar to younger patients are achievable with higher
imatinib doses applied early in the course of treatment, in
Years after diagnosis
Age, years n AP/BC, n 5 year CI, % p
IM800 ≥ 65 83 2 2.6
ns
IM800 < 65 319 20 6.7
IM400 ≥ 65 110 6 6.3
ns
IM400 < 65 272 15 5.6
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Fig. 3 Progression to AP and BC
according to treatment groups. AP
accelerated phase, BC blast crisis,
n number of patients, CI
cumulative incidence, IM400
imatinib 400 mg/day, IM800
imatinib 800 mg/day, ns not
significant
Table 4 Causes of death
n number of patients, IM400
imatinib 400 mg/day, IM800
imatinib 800 mg/day, AP
accelerated phase, BC blast crisis,
CP chronic phase
IM400 IM800
Age (years), (n) <65 (272) ≥65 (110) <65 (319) ≥65 (83)
Total deaths (n) 23 21 19 6
Causes (n)
Progression to AP/BC 8 4 9 1
Transplantation related 3 0 4 0
Infection in CP 2 0 2 1
Secondary malignancy 1 8 1 2
Bleeding 1 0 1 0
Cardiopulmonary 2 2 1 1
Renal insufficiency 0 2 0 1
Thromboembolic/ischemic (not cardiac) 0 1 1 0
Suicide 0 1 0 0
Others 3 0 0 0
Unknown 3 3 0 0
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contrast to standard-dose imatinib. It seems that the optimal
daily dose for patients with CP CML is higher than 400 mg,
irrespective of age.
Acknowledgments The authors would like to thank Gabriele Bartsch,
Uwe Böhm, Elke Matzat, Sabine Dean, Ute Kossak-Roth, Barbara Müll-
er, Regina Pleil-Lösch, Nicole Schomber, Inge Stalljann, Andrea Poetsch,
the Steering Group (Rüdiger Hehlmann, Gerhard Ehninger, Joerg
Hasford, Andreas Hochhaus, Dieter Hossfeld, Hans-Jochem Kolb, Stefan
W. Krause, Christoph Nerl, Andreas Neubauer, Dominik Heim, Gabriela
M. Baerlocher, Hermann Heimpel), and all CML trial participants. The
CML-Study IV is supported by the Deutsche Krebshilfe (Nr. 106642 and
109588), Novartis, (Nürnberg, Germany), Kompetenznetz für Akute and
Chronische Leukämien (BMBF 01GI0270), José-Carreras
Leukämiestiftung (DJCLS H09/01f, H06/04v, H03/01, R05/23), the Eu-
ropean LeukemiaNet (LSHC-CT-2004-503216), Roche, and Essex
Pharma.
Conflict of interest MCM was supported by Novartis (consultation or
other fees, research funding, other relationships), Bristol-Myers Squibb
(consultation or other fees, research funding, other relationships), and
ARIAD (consultation or other fees, research funding, other relationships).
MP was also supported by Novartis (consultation or other fees) and
Bristol-Myers Squibb (lecture fees). AH received financial support from
Novartis (consultation or other fees, lecture fees, research funding),
Bristol-Myers Squibb (consultation or other fees, lecture fees), ARIAD
(consultation or other fees, lecture fees), and Pfizer (consultation or other
fees, lecture fees). RH was supported by Bristol-Myers Squibb (consul-
tation or other fees, research funding) andNovartis (research funding). SS
received sponsorship from Novartis (consultation or other fees, research
funding, other relationships), Bristol-Myers Squibb (consultation or other
fees, research funding), and Pfizer (consultation or other fees).
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K,
Lahaye T, Saussele S, Müller MC, Hasford J, Heimpel H, Hehlmann
R (2009) Clinical trials underestimate the age of chronic myeloid
leukemia (CML) patients. Incidence and median age of Ph/BCR-
ABL-positive CML and other chronic myeloproliferative disorders in
a representative area in Germany. Leukemia 23(3):602–604. doi:10.
1038/leu.2008.245
2. BjörkholmM,OhmL, Eloranta S, Derolf A, HultcrantzM, Sjöberg J,
Andersson T, Höglund M, Richter J, Landgren O, Kristinsson SY,
Dickman PW (2011) Success story of targeted therapy in chronic
myeloid leukemia: a population-based study of patients diagnosed in
Sweden from 1973 to 2008. J Clin Oncol 29(18):2514–2520. doi:10.
1200/jco.2011.34.7146
3. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R,
Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A,
Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb
DG, Edwards BK (eds) (based on November 9 SEER data submis-
sion, posted to the SEER web site, 2010 ) SEER cancer statistics
review, 1975–2007: median age of cancer patients at diagnosis,
2003–2007 by primary cancer site, race and sex. http://seer.cancer.
gov/csr/1975_2007/results_single/sect_01_table.11_2pgs.pdf,
National Cancer Institute, Bethesda, MD
4. Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid
leukaemia (CML). Best Pract Res Clin Haematol 22(3):295–302.
doi:10.1016/j.beha.2009.07.007
5. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H,
Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM,
Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P,
Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G,
Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson
B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, or the IRIS
Investigators (2006) Five-year follow-up of patients receiving ima-
tinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–
2417. doi:10.1056/NEJMoa062867
6. Berger U, Engelich G, Maywald O, Pfirrmann M, Hochhaus A,
Reiter A, Metzgeroth G, Gnad U, Hasford J, Heinze B, Heimpel H,
Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann
R, and the German CML-Study Group (2003) Chronic myeloid
leukemia in the elderly: long-term results from randomized trials with
interferon alpha. Leukemia 17(9):1820–1826. doi:10.1038/sj.leu.
2403042
7. Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D,
Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F,
Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani
M, Martinelli G (2007) Impact of age on the outcome of patients with
chronic myeloid leukemia in late chronic phase: results of a phase II
study of the GIMEMA CMLWorking Party. Haematologica 92(1):
101–105. doi:10.3324/haematol.10239
8. Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R,
Diverio D, Frustaci A, Loglisci G, Mancini M, Santopietro M,
Stefanizzi C, Volpicelli P, Vozella F, Alimena G (2010) “Real- life”
results of front-line treatment with Imatinib in older patients (≥65
years) with newly diagnosed chronic myelogenous leukemia. Leuk
Res 34(11):1472–1475. doi:10.1016/j.leukres.2010.07.001
9. Cortes J, Talpaz M, O’Brien S, Giles F, Beth Rios M, Shan J, Faderl
S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H (2003)
Effects of age on prognosis with imatinib mesylate therapy for
patients with Philadelphia chromosome-positive chronic myeloge-
nous leukemia. Cancer 98(6):1105–1113. doi:10.1002/cncr.11629
10. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T,
Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F,
Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi
G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G,
Baccarani M, Rosti G, and on behalf of the Gruppo Italiano Malattie
Ematologiche dell’Adulto CMLWorking Party (2011) Frontline ima-
tinib treatment of chronic myeloid leukemia: no impact of age on
outcome, a survey by the GIMEMA CML Working Party. Blood
117(21):5591–5599. doi:10.1182/blood-2010-12-324228
11. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ,
Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A,
McDougall K, Albitar M, Radich J, on behalf of the Rationale and
Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group
(2009) High-dose imatinib in newly diagnosed chronic-phase chronic
myeloid leukemia: high rates of rapid cytogenetic and molecular
responses. J Clin Oncol 27(28):4754–4759. doi:10.1200/jco.2008.
20.3869
12. Rousselot P, Cony-Makhoul P, Nicolini F, Mahon FX, Berthou C,
Réa D, Reiffers J, Bornand A, Saint-Jean O, Guilhot J, Guilhot F, on
behalf of the French Intergroup For Chronic Myelogenous Leukemia
(Fi-LMC) (2013) Long-term safety and efficacy of imatinib mesylate
(Gleevec®) in elderly patients with chronic phase chronic myeloge-
nous leukemia: Results of the AFR04 study. Am J Hematol 88(1):1–
4. doi:10.1002/ajh.23330
13. Sánchez-Guijo FM, Durán S, Galende J, Boqué C, Nieto JB,
Balanzat J, Gracia A, García I, Avellaneda-Molina C, Moreno M-V,
Ann Hematol (2014) 93:1167–1176 1175
Luño-Fernandez E, Hermosilla M, Sanchez-Varela JM, Dios A,
Lopez-Garrido P, Giraldo P, Bargay J, Domingo JM, Soler A,
Salinas R, del Cañizo MC (2011) Evaluation of tolerability and
efficacy of imatinib mesylate in elderly patients with chronic phase
CML: ELDERGLI study. Leuk Res 35(9):1184–1187. doi:10.1016/j.
leukres.2011.01.017
14. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Mueller
MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen
L, Hänel M, PfirrmannM, Krause SW, Nerl C, Pralle H, Gratwohl A,
Hossfeld DK, Hasford J, Hochhaus A, Saussele S, (2011)
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400
mg/d plus interferon-alpha in newly diagnosed chronic myeloid
leukemia. J Clin Oncol 29(12):1634–1642. doi:10.1200/jco.2010.
32.0598
15. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A,
Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C,
Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A,
Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann
K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause
SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A
(2014) Deep molecular response (MR4.5) is reached by the majority
of imatinib-treated patients, predicts survival, and is achieved faster
by optimized high-dose imatinib—results from the randomized
CML-Study IV. J Clin Oncol 32(5):415–423. doi:10.1200/JCO.
2013.49.9020
16. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B,
Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A,
Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J,
Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M,
Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K,
Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S,
Hehlmann R, and for the Schweizerische Arbeitsgemeinschaft für
Klinische Krebsforschung (SAKK) and the German CML Study
Group (2011) Impact of additional cytogenetic aberrations at diag-
nosis on prognosis of CML: long-term observation of 1151 patients
from the randomized CML Study IV. Blood 118(26):6760–6768 doi:
10.1182/blood-2011-08-373902
17. Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M,
Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb
HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J,
Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F,
Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann
K, Baerlocher GM, PfirrmannM, Hasford J, Saußele S, Hochhaus A,
for the SAKK and the German CML Study Group (2012) Early
molecular and cytogenetic response is predictive for long-term
progression-free and overall survival in chronic myeloid leukemia
(CML). Leukemia 26(9):2096–2102. doi:10.1038/leu.2012.85
18. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D,
Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok
G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C,
Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner
A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R, and for the
German CML-Study Group (2010) Allogeneic hematopoietic stem
cell transplantation (allo SCT) for chronic myeloid leukemia in the
imatinib era: evaluation of its impact within a subgroup of the
randomized German CML Study IV. Blood 115(10):1880–1885.
doi:10.1182/blood-2009-08-237115
19. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S,
Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-
Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton
JH, Mahon F-X, Martinelli G, Mayer J, Müller MC, Niederwieser D,
Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C,
Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R
(2013) European LeukemiaNet recommendations for the manage-
ment of chronic myeloid leukemia: 2013. Blood 122(6):872–884.
doi:10.1182/blood-2013-05-501569
20. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A (2012)
Standardized definitions of molecular response in chronic myeloid
leukemia. Leukemia 26(10):2172–2175. doi:10.1038/leu.2012.104
21. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M,
Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A
new prognostic score for survival of patients with chronic myeloid
leukemia treated with interferon alfa. Writing Committee for the
Collaborative CML Prognostic Factors Project Group. J Natl
Cancer Inst 90(11):850–858. doi:10.1093/jnci/90.11.850
22. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G,
Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B,
Pfirrmann M, Hehlmann R (2011) Predicting complete cytogenetic
response and subsequent progression-free survival in 2060 patients
with CML on imatinib treatment: the EUTOS score. Blood 118(3):
686–692. doi:10.1182/blood-2010-12-319038
23. Gooley TA, LeisenringW, Crowley J, Storer BE (1999) Estimation of
failure probabilities in the presence of competing risks: new repre-
sentations of old estimators. Stat Med 18(6):695–706
24. Pfirrmann M, Hochhaus A, Lauseker M, Saußele S, Hehlmann R,
Hasford J (2011) Recommendations to meet statistical challenges
arising from endpoints beyond overall survival in clinical trials on
chronic myeloid leukemia. Leukemia 25(9):1433–1438. doi:10.
1038/leu.2011.116
25. Gray RJ (1988) A class of k-sample tests for comparing the cumula-
tive incidence of a competing risk. Ann Stat 16(3):1141–1154. doi:
10.1214/aos/1176350951
26. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J,
Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D,
Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G,
Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring
CML patients responding to treatment with tyrosine kinase inhibitors:
review and recommendations for harmonizing current methodology
for detecting BCR-ABL transcripts and kinase domain mutations and
for expressing results. Blood 108(1):28–37 doi:10.1182/blood-2006-
01-0092
27. Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T,
Hehlmann R, Branford S, Saglio G, Hochhaus A (2009)
Harmonization of molecular monitoring of CML therapy in Europe.
Leukemia 23(11):1957–1963. doi:10.1038/leu.2009.168
28. Statistical Yearbook for the Federal Republic of Germany including
“International tables” (2011) Federal Statistical Office, Wiesbaden
29. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW,
Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe
JM, Tothova E, De Souza C, RudoltzM,Yu R,Krahnke T, Kantarjian
HM, Radich JP, Hughes TP (2010) Phase III, randomized, open-label
study of daily imatinib mesylate 400 mg versus 800 mg in patients
with newly diagnosed, previously untreated chronic myeloid leuke-
mia in chronic phase using molecular end points: tyrosine kinase
inhibitor optimization and selectivity study. J Clin Oncol 28(3):424–
430. doi:10.1200/JCO.2009.25.3724
30. Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M,
Smith TL, Freireich EJ (1987) Old age: a sign of poor prognosis in
patients with chronic myelogenous leukemia. South Med J 80(10):
1228–1232
1176 Ann Hematol (2014) 93:1167–1176
